- Home
- GCI vs DNTH Comparison
GCI vs DNTH Comparison
Compare GCI & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCI
- DNTH
- Stock Information
- Founded
- GCI 1997
- DNTH 2015
- Country
- GCI United States
- DNTH United States
- Employees
- GCI N/A
- DNTH N/A
- Industry
- GCI Newspapers/Magazines
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- GCI Consumer Discretionary
- DNTH Health Care
- Exchange
- GCI Nasdaq
- DNTH Nasdaq
- Market Cap
- GCI 734.1M
- DNTH 670.7M
- IPO Year
- GCI N/A
- DNTH N/A
- Fundamental
- Price
- GCI $4.61
- DNTH $22.29
- Analyst Decision
- GCI Buy
- DNTH Strong Buy
- Analyst Count
- GCI 3
- DNTH 9
- Target Price
- GCI $5.70
- DNTH $46.43
- AVG Volume (30 Days)
- GCI 955.3K
- DNTH 245.5K
- Earning Date
- GCI 02-20-2025
- DNTH 03-20-2025
- Dividend Yield
- GCI N/A
- DNTH N/A
- EPS Growth
- GCI N/A
- DNTH N/A
- EPS
- GCI N/A
- DNTH N/A
- Revenue
- GCI $2,557,445,000.00
- DNTH $5,366,000.00
- Revenue This Year
- GCI N/A
- DNTH $100.14
- Revenue Next Year
- GCI N/A
- DNTH N/A
- P/E Ratio
- GCI N/A
- DNTH N/A
- Revenue Growth
- GCI N/A
- DNTH 51.41
- 52 Week Low
- GCI $1.95
- DNTH $18.35
- 52 Week High
- GCI $5.93
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- GCI 41.15
- DNTH 49.77
- Support Level
- GCI $4.30
- DNTH $21.28
- Resistance Level
- GCI $4.74
- DNTH $23.28
- Average True Range (ATR)
- GCI 0.20
- DNTH 1.75
- MACD
- GCI -0.02
- DNTH 0.17
- Stochastic Oscillator
- GCI 33.52
- DNTH 79.92
About GCI Gannett Co. Inc.
Gannett Co Inc is a digital newspaper company providing local media and marketing solutions in the U.S. The group operates in three segments, Domestic Gannett Media, Newsquest, and Digital Marketing Solutions. The majority of revenue is from the Domestic Gannett Media segment. The company's brands include USA TODAY and more than 250 daily newspapers as well as digital marketing services companies, including ReachLocal, WordStream, and others. The company produces more than 350 annual events, such as themed expos. The company also operates in the U.K. through the U.K. media company Newsquest, providing more than 150 local media brands.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.